Evidence map›Paper›PMID 41285132›Full record

ArticleThe Lancet. Oncology2025

Carcinogenicity of atrazine, alachlor, and vinclozolin.

Russell C Cattley, Anneclaire J De Roos, Daniele Mandrioli, Neil Pearce, Anjoeka Pronk, Anatoly Soshilov, Sunny O Abarikwu, Isabelle Baldi, Dana B Barr, Laura E Beane Freeman and 28 more

Erratum issuedAbstract read
In one paragraph

Article in The Lancet. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors.

Russell C CattleyInternational Agency for Research on Cancer, Lyon, France.
Anneclaire J De RoosInternational Agency for Research on Cancer, Lyon, France.
Daniele MandrioliInternational Agency for Research on Cancer, Lyon, France.
Neil PearceInternational Agency for Research on Cancer, Lyon, France.
Anjoeka PronkInternational Agency for Research on Cancer, Lyon, France.
Anatoly SoshilovInternational Agency for Research on Cancer, Lyon, France.
Sunny O AbarikwuInternational Agency for Research on Cancer, Lyon, France.
Isabelle BaldiInternational Agency for Research on Cancer, Lyon, France.
Dana B BarrInternational Agency for Research on Cancer, Lyon, France.
Laura E Beane FreemanInternational Agency for Research on Cancer, Lyon, France.
Sylvie BortoliInternational Agency for Research on Cancer, Lyon, France.
Alison ConnollyInternational Agency for Research on Cancer, Lyon, France.
Mohamed A DalvieInternational Agency for Research on Cancer, Lyon, France.
Marcelo Jm FerreiraInternational Agency for Research on Cancer, Lyon, France.
Mary Beth GenterInternational Agency for Research on Cancer, Lyon, France.
Ludovic Le HégaratInternational Agency for Research on Cancer, Lyon, France.
Stefano LorenzettiInternational Agency for Research on Cancer, Lyon, France.
John R McLaughlinInternational Agency for Research on Cancer, Lyon, France.
Peter MøllerInternational Agency for Research on Cancer, Lyon, France.
Cassiana C MontagnerInternational Agency for Research on Cancer, Lyon, France.
Henrique C S SilveiraInternational Agency for Research on Cancer, Lyon, France.
Takeshi ToyodaInternational Agency for Research on Cancer, Lyon, France.
David H VolleInternational Agency for Research on Cancer, Lyon, France.
Lamia Benbrahim-TallaaInternational Agency for Research on Cancer, Lyon, France.
Aline de ContiInternational Agency for Research on Cancer, Lyon, France.
Caterina FacchinInternational Agency for Research on Cancer, Lyon, France.
Andrew T KunzmannInternational Agency for Research on Cancer, Lyon, France.
Federica MadiaInternational Agency for Research on Cancer, Lyon, France.
Elisa PasqualInternational Agency for Research on Cancer, Lyon, France.
Marie-Laure AixInternational Agency for Research on Cancer, Lyon, France.
Xiaobei DengInternational Agency for Research on Cancer, Lyon, France.
Rachmad A DongoranInternational Agency for Research on Cancer, Lyon, France.
Michael T OlanipekunInternational Agency for Research on Cancer, Lyon, France.
Eero SuonioInternational Agency for Research on Cancer, Lyon, France.
Susana ViegasInternational Agency for Research on Cancer, Lyon, France.
Heidi MattockInternational Agency for Research on Cancer, Lyon, France.
Roland WedekindInternational Agency for Research on Cancer, Lyon, France.
Mary K Schubauer-BeriganInternational Agency for Research on Cancer, Lyon, France.

Funding

IARC Monographs on the Identification of Carcinogenic Hazards to HumansR01CA033193 · NCI · INTERNATIONAL AGENCY FOR RES ON CANCER · PI SCHUBAUER-BERIGAN, MARY K. · 2021 to 2025
$4.9M
NCI NIH HHS R01 CA033193World Health Organization 001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41285132
PMCPMC12729129

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.